NCT02892851

Brief Summary

Cocaine addiction is a chronic condition with severe cardiac, neurologic, psychiatric and social complications. Cocaine is the second most consumed illicit drug in France. Its prevalence has been multiplied by 3 between 2000 and 2008, and is still on the rise. Craving, the compulsive need to consume, is a key feature of cocaine addiction. It is also predictive of treatment efficacy. However, there is no validated treatment for severe cocaine dependence yet. Response to current psychological and medical treatment is poor, with 73% relapse after 3 months. Patients with severe cocaine addiction are thus in a therapeutic deadlock. To address these unmet medical needs, the investigators designed a pilot study (n=2) to evaluate the safety and the efficacy of the deep brain stimulation of the subthalamic nuclei (STN-DBS) in severe cocaine addiction with at least one cardiac, neurologic or psychiatric complication. Indeed, compulsivity is a critical component of craving, and severe treatment-resistant obsessive compulsive disorder (OCD) are already successfully treated using STN-DBS. Moreover, animal studies recently demonstrated a therapeutic effect of STN-DBS in rats addicted to cocaine. Together, these two lines of research suggest a therapeutic effect of STN-DBS in cocaine addiction mediated by an anti-obsessive mechanism on craving.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
2

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Mar 2014

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 1, 2014

Completed
2.5 years until next milestone

First Submitted

Initial submission to the registry

August 18, 2016

Completed
21 days until next milestone

First Posted

Study publicly available on registry

September 8, 2016

Completed
12 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2017

Completed
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2018

Completed
Last Updated

September 8, 2016

Status Verified

August 1, 2016

Enrollment Period

3.5 years

First QC Date

August 18, 2016

Last Update Submit

September 1, 2016

Conditions

Keywords

STN-DBSCravingCocaine addiction

Outcome Measures

Primary Outcomes (1)

  • Evolution of the Obsessive Compulsive Cocaine Scale (OCCS) craving score

    at month 6

Secondary Outcomes (6)

  • Psychiatric assessment by standardized interview

    Month -2, Month 2, Month 3, Month 3+15 days, Month 4+15days, Month 6, Month 7, Month 8, Month 9, Month10 (+1,5)

  • Cocaine Craving Questionnaire (CCQ) craving score

    Month -2, Month 2 (1day), Month 2 (2nd day), Month 2 (3rd day), Month 3, Month 3+15 days, Month 4+15days, Month 6, Month 7, Month 8, Month 9, Month 10 (+1,5)

  • Self assessed addiction criteria

    Month -2, Month 2, Month 3, Month 3+15 days, Month 4+15days, Month 6, Month 7, Month 8, Month 9, Month10 (+1,5)

  • Urine screening assay for cocaine use / Urine Drug Screening

    Month -2, Month 2, Month 3, Month 3+15 days, Month 4+15days, Month 6, Month 7, Month 8, Month 9, Month10 (+1,5)

  • Capillary screening assay for cocaine use

    Month -2, Month 4,5 and Month 10 (+1,5)

  • +1 more secondary outcomes

Study Arms (1)

Deep brain stimulation (DBS)

EXPERIMENTAL

Deep brain stimulation of the subthalamic nuclei (STN-DBS)

Device: Deep brain stimulation of the subthalamic nuclei (STN-DBS)

Interventions

3 phases : * Parameter setting * Cross-over double-bind (ON/OFF) * Open Phase (ON)

Also known as: Activa PC Medtronic (7428) stimulator
Deep brain stimulation (DBS)

Eligibility Criteria

Age30 Years - 55 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • severe and resistant Cocaine Dependence for 5 years defined as:
  • cocaine dependence (DSM IV),
  • preferential use of cocaine in base form (crack or free-base) through smoke,
  • non response to at least two well-conducted treatment with at least a stay in aftercare,
  • severe physical complications (defined as a history of myocardial infarction, stroke).
  • psychotic syndromes induced recurrent, severe lung disease "crack-lungs") occurred due to crack consumption and whose association with the crack use is known to the patient
  • age between 30 and 55 years
  • patient affiliated to a social security scheme
  • patient signed an informed consent after receiving written information on the proposed procedure

You may not qualify if:

  • patient trust
  • pregnant, nursing or of childbearing potential without effective contraception
  • current use of the intravenous route for the administration of the drugs is the risk of infection
  • VIH infection or VHC unstabilized,
  • cardiovascular and / or brain state is not compatible with the surgery,
  • other disorder on Axis I not linked to cocaine use except:
  • current or past dependence to nicotine,
  • abuse or dependence on other psychoactive substances over a lifetime in remission for more than 6 months,
  • current opioid dependence: if the patient is undergoing substitution treatment (methadone or buprenorphine) and not injection of opiates for at least 6 months,
  • when other psychiatric disorders induced by substances.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Henri Mondor Hospital

Créteil, 94010, France

RECRUITING

MeSH Terms

Conditions

Cocaine-Related Disorders

Condition Hierarchy (Ancestors)

Substance-Related DisordersChemically-Induced DisordersMental Disorders

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 18, 2016

First Posted

September 8, 2016

Study Start

March 1, 2014

Primary Completion

September 1, 2017

Study Completion

March 1, 2018

Last Updated

September 8, 2016

Record last verified: 2016-08

Data Sharing

IPD Sharing
Will not share

Locations